Assessment cycle 2026 Q3 — page 4
Documents ratified in the 2026 Q3 assessment cycle, which ran from 1 July 2026 to 30 September 2026 and was ratified on 18 September 2026.
Documents ratified
-
New England Journal of Medicine 2023
30 Jul 2026 -
WHO Medical Product Alert 2024
30 Jul 2026 -
WHO Technical Report Series 2023
30 Jul 2026 -
New England Journal of Medicine 2021
30 Jul 2026 -
Diabetes, Obesity and Metabolism 2022
30 Jul 2026 -
Consultation on the fourth version of the Institute's methodology document, which describes how a question is registered, how evidence is searched and screened, how…
31 Jul 2026 -
Consultation on the draft certainty index, a cross-cutting finding aid that lists every assessed outcome in the document set by its certainty rating. The index makes it…
10 Jul 2026 -
Consultation on the draft monograph for amycretin, a co-agonist at the glucagon-like peptide-1 and amylin receptors. The draft grades the principal assessed outcome at…
05 Aug 2026 -
Consultation on the draft monograph for CJC-1295, which the assessment committee released for public comment before ratification. The draft grades the compound's…
21 Jul 2026 -
Consultation on the draft monograph for Exenatide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
07 Aug 2026 -
Consultation on the draft monograph for SS-31 (elamipretide), which the assessment committee released for public comment before ratification. The draft grades the…
04 Jul 2026 -
Consultation on the draft of CEI-MS-07, which specifies the performance a determination must achieve for physical quality and states what the resulting figure does not…
21 Jul 2026 -
Consultation on the draft of CEI-MS-13, which specifies the performance a determination must achieve for method validation and states what the resulting figure does not…
04 Jul 2026 -
Consultation on the draft of this analytical evidence review, which registers the question: What is known about bacterial endotoxin content in peptides supplied for…
10 Aug 2026 -
Consultation on the draft of this analytical evidence review, which registers the question: How much does a reported chromatographic purity figure vary with the method…
19 Jul 2026 -
Consultation on the draft of this intervention review, which registers the question: What randomised evidence supports mitochondria-targeted peptides in primary…
14 Jul 2026 -
In adults with obesity, does a multi-receptor incretin agonist produce a larger reduction in body weight than a single glucagon-like peptide-1 receptor agonist?
Moderate19 Aug 2026 -
How large is the discrepancy between labelled peptide mass and delivered peptide mass when counter-ion and water content are not reported?
High01 Sep 2026 -
What do published analytical surveys report about the identity, purity and content of peptides obtained from unregulated suppliers?
Low31 Aug 2026 -
What is the effect of an amylin receptor agonist alone and in combination with a glucagon-like peptide-1 receptor agonist on body weight?
Moderate10 Aug 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Exenatide compared with the comparator used in its contributing trials on the anchor…
High28 Jul 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Survodutide compared with the comparator used in its contributing trials on the…
Moderate05 Sep 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Liraglutide compared with the comparator used in its contributing trials on the…
High20 Aug 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the effect of Gonadorelin compared with the comparator used…
Moderate29 Aug 2026 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the incidence of adverse events leading to discontinuation with…
Moderate07 Sep 2026 -
In the population defined for immune modulation and adjunctive immunotherapy, is the effect of Thymosin alpha-1 maintained across the full duration of the contributing…
Moderate26 Aug 2026 -
The Institute’s judgement of the extent to which an effect estimate is adequate to support a conclusion. Reported at one of four levels: high, moderate, low or very low…
30 Jul 2026 -
The Institute is confident that the true effect lies close to the estimate. Further research is very unlikely to change confidence in the estimate. A high rating is not…
30 Jul 2026 -
The true effect is likely to be close to the estimate, but there is a real possibility that it is substantially different. Further research is likely to have an…
30 Jul 2026 -
Confidence in the effect estimate is limited and the true effect may be substantially different. The Institute states in each case whether the limitation arises from…
30 Jul 2026 -
The Institute has very little confidence in the effect estimate. In this document set a very low rating most often reflects an absence of controlled human evidence…
30 Jul 2026 -
A state in which no study adequate to answer a question has been identified. The Institute records an absence of evidence as distinct from evidence of absence: the first…
30 Jul 2026 -
A finding, from a study adequately powered to detect an effect of the size of interest, that no such effect was observed. A negative result from an adequately powered…
30 Jul 2026 -
The reduction of a certainty rating from its starting level because of a concern in one of five domains: risk of bias, inconsistency, indirectness, imprecision and…
30 Jul 2026 -
The increase of a certainty rating above its starting level, applicable in principle to observational evidence showing a large effect, a dose–response gradient or a…
30 Jul 2026 -
The extent to which features of a study’s design or conduct could produce an effect estimate that systematically departs from the truth. Assessed at the level of the…
30 Jul 2026 -
A mismatch between the population, intervention, comparator or outcome of the contributing studies and those of the question being answered. Also applied where an…
30 Jul 2026 -
A confidence interval wide enough that its ends would support different decisions, or an event count too small to constrain the estimate. Assessed against a decision…
30 Jul 2026 -
Unexplained variation in effect estimates across contributing studies, beyond what chance would produce. Consistency of direction with variation in magnitude is treated…
30 Jul 2026 -
The risk that the studies available to a review are not a representative sample of the studies conducted, most often because studies with unfavourable results were not…
30 Jul 2026
page 4 of 14